These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 29922655)

  • 21. Hepatic Encephalopathy in Cirrhotic Patients and Risk of Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-Analysis.
    Feng X; Li X; Zhang X; Chen W; Tian Y; Yang Q; Yang Y; Pan H; Jiang Z
    Biomed Res Int; 2022; 2022():2469513. PubMed ID: 36303585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?
    Fukui H
    Diseases; 2019 Nov; 7(4):. PubMed ID: 31726747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small-intestinal bacterial overgrowth in patients with liver cirrhosis, diagnosed with glucose H2 or CH4 breath tests.
    Yang CY; Chang CS; Chen GH
    Scand J Gastroenterol; 1998 Aug; 33(8):867-71. PubMed ID: 9754736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of a Probiotic Containing
    Efremova I; Maslennikov R; Zharkova M; Poluektova E; Benuni N; Kotusov A; Demina T; Ivleva A; Adzhieva F; Krylova T; Ivashkin V
    J Clin Med; 2024 Feb; 13(3):. PubMed ID: 38337613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gut microbiota-related complications in cirrhosis.
    Gómez-Hurtado I; Such J; Sanz Y; Francés R
    World J Gastroenterol; 2014 Nov; 20(42):15624-31. PubMed ID: 25400446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Could antioxidants be the "magic pill" for cirrhosis-related complications? A pathophysiological appraisal.
    Assimakopoulos SF; Gogos C; Labropoulou-Karatza C
    Med Hypotheses; 2011 Sep; 77(3):419-23. PubMed ID: 21703771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients.
    Jun DW; Kim KT; Lee OY; Chae JD; Son BK; Kim SH; Jo YJ; Park YS
    Dig Dis Sci; 2010 May; 55(5):1465-71. PubMed ID: 19517230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023?
    Gudan A; Kozłowska-Petriczko K; Wunsch E; Bodnarczuk T; Stachowska E
    Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PERIPHERAL BLOOD ENDOTOXIN LEVELS ARE NOT ASSOCIATED WITH SMALL INTESTINAL BACTERIAL OVERGROWTH IN NONALCOHOLIC FATTY LIVER DISEASE WITHOUT CIRRHOSIS.
    GuimarÃes VM; Santos VN; Borges PSA; DE Farias JLR; Grillo P; Parise ER
    Arq Gastroenterol; 2020; 57(4):471-476. PubMed ID: 33331479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of intestinal bacterial overgrowth and intestinal motility in bacterial translocation in experimental cirrhosis.
    Sánchez E; Casafont F; Guerra A; de Benito I; Pons-Romero F
    Rev Esp Enferm Dig; 2005 Nov; 97(11):805-14. PubMed ID: 16438624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intestinal permeability in a patient with liver cirrhosis.
    Aguirre Valadez JM; Rivera-Espinosa L; Méndez-Guerrero O; Chávez-Pacheco JL; García Juárez I; Torre A
    Ther Clin Risk Manag; 2016; 12():1729-1748. PubMed ID: 27920543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mosapride Stabilizes Intestinal Microbiota to Reduce Bacterial Translocation and Endotoxemia in CCl
    Xu H; Xiong J; Xu J; Li S; Zhou Y; Chen D; Cai X; Ping J; Deng M; Chen J
    Dig Dis Sci; 2017 Oct; 62(10):2801-2811. PubMed ID: 28815345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature.
    Pijls KE; Jonkers DM; Elamin EE; Masclee AA; Koek GH
    Liver Int; 2013 Nov; 33(10):1457-69. PubMed ID: 23879434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease.
    Pande C; Kumar A; Sarin SK
    Aliment Pharmacol Ther; 2009 Jun; 29(12):1273-81. PubMed ID: 19302262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function.
    Madrid AM; Hurtado C; Venegas M; Cumsille F; Defilippi C
    Am J Gastroenterol; 2001 Apr; 96(4):1251-5. PubMed ID: 11316178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimal Hepatic Encephalopathy: Effect of H. pylori infection and small intestinal bacterial overgrowth treatment on clinical outcomes.
    Abid S; Kamran M; Abid A; Butt N; Awan S; Abbas Z
    Sci Rep; 2020 Jun; 10(1):10079. PubMed ID: 32572109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.
    Tsiaoussis GI; Assimakopoulos SF; Tsamandas AC; Triantos CK; Thomopoulos KC
    World J Hepatol; 2015 Aug; 7(17):2058-68. PubMed ID: 26301048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease.
    Augustyn M; Grys I; Kukla M
    Clin Exp Hepatol; 2019 Mar; 5(1):1-10. PubMed ID: 30915401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension.
    Gunnarsdottir SA; Sadik R; Shev S; Simrén M; Sjövall H; Stotzer PO; Abrahamsson H; Olsson R; Björnsson ES
    Am J Gastroenterol; 2003 Jun; 98(6):1362-70. PubMed ID: 12818282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites.
    Pérez-Paramo M; Muñoz J; Albillos A; Freile I; Portero F; Santos M; Ortiz-Berrocal J
    Hepatology; 2000 Jan; 31(1):43-8. PubMed ID: 10613726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.